Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 84, Issue 1, 2009, Pages 34-38

  Kjær, Andreas ^a,b   Kristoffersen, Ulrik Sloth ^a,b   Tarnow, Lise ^c   Parving, Hans Henrik ^b   Hesse, Birger ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

Coronary arteries; Positron emission tomography; Type 2 diabetes; Vasomotor function

Indexed keywords

AMMONIA N 13; DIPYRIDAMOLE; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEART MUSCLE PERFUSION; HEART RATE; HEART STRESS; HUMAN; HYPEREMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; RECOMMENDED DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; LOSARTAN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 62049085401     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.01.010     Document Type: Article

References (21)

1. Nabel E.G., Selwyn A.P., and Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J. Am. Coll. Cardiol. 16 August (2) (1990) 349-356
2. Zeiher A.M., Schachinger V., Weitzel S.H., Wollschlager H., and Just H. Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. Circulation 83 May (5) (1991) 1519-1525
3. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Thomas O., et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br. Heart J. 74 September (3) (1995) 247-253
4. Beanlands R.S., Muzik O., Melon P., Sutor R., Sawada S., Muller D., et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography: determination of extent of altered vascular reactivity. J. Am. Coll. Cardiol. 26 November (6) (1995) 1465-1475
5. Demer L.L., Gould K.L., Goldstein R.A., Kirkeeide R.L., Mullani N.A., Smalling R.W., et al. Assessment of coronary artery disease severity by positron emission tomography: comparison with quantitative arteriography in 193 patients. Circulation 79 April (4) (1989) 825-835
6. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 December (6) (1993) 2510-2516
7. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27 March (3) (1996) 567-574
8. Hesse B., Meyer C., Nielsen F.S., Sato A., Hove J.D., Holm S., et al. Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition. Eur. J. Nucl. Med. Mol. Imaging 31 March (3) (2004) 362-368
9. Kjaer A., Meyer C., Nielsen F.S., Parving H.H., and Hesse B. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J. Nucl. Med. 44 January (1) (2003) 19-23
10. H.G. Lovell, Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria, Cochrane Database Syst Rev (2) (2000), CD002183.
11. Malik R.A. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?. Ann. Med. 32 February (1) (2000) 1-5
12. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 January (3) (2000) 145-153
13. O'Driscoll G., Green D., Rankin J., Stanton K., and Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 100 August (3) (1997) 678-684
14. Arcaro G., Zenere B.M., Saggiani F., Zenti M.G., Monauni T., Lechi A., et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 22 September (9) (1999) 1536-1542
15. O'Driscoll G., Green D., Maiorana A., Stanton K., Colreavy F., and Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 33 May (6) (1999) 1506-1511
16. Rossing K., Jacobsen P., Pietraszek L., and Parving H.H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26 August (8) (2003) 2268-2274
17. Jacobsen P., Andersen S., Rossing K., Jensen B.R., and Parving H.H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 63 May (5) (2003) 1874-1880
18. Kjaer A., Meyer C., Wachtell K., Olsen M.H., Ibsen H., Opie L., et al. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. Am. J. Cardiol. 96 December (12) (2005) 1692-1698
19. Giugliano D., Marfella R., Acampora R., Giunta R., Coppola L., and D'Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 21 April (4) (1998) 631-636
20. Moon C.H., Lee H.J., Jung Y.S., Lee S.H., and Baik E.J. Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. Res. Commun. Mol. Pathol. Pharmacol. 101 August (2) (1998) 147-158
21. Schindler T.H., Facta A.D., Prior J.O., Cadenas J., Hsueh W.A., Quinones M.J., et al. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. Heart 93 March (3) (2007) 345-349